Czech Health Research Council

• Germline, weakly activating JAK2 variants predisposing to myeloid malignancies: cooperation with driver leukemogenic oncogene; NU21-03-00338 ; 2021-2024.
• Searching and functional testing of gene variants predisposing to familial haematopoietic disorders; NU20-08-00137, 2020-2023
• Genomic characterization of adult B-precursor acute lymphoblastic leukemia for prediction of treatment response to targeted therapy; NU22-03-00210, 2022-2025

All Target:

• A precision medicine randomized trial for patients with relapsed or refractory T-cell Acute Lymphoblastic Leukemia based on a functional approach (European Programme ATTRACT, European Working Group on Acute Lymphoblastic Leukaemia EWALL), 2024-2029

Technology Agency of the Czech Republic:

• Personalized Medicine – Diagnostics and Therapy; TN01000013, 2019-2022